PT  - JOURNAL ARTICLE
AU  - Fischer, Bastian
AU  - Lichtenberg, Christoph
AU  - Müller, Lisa
AU  - Timm, Jörg
AU  - Fischer, Johannes
AU  - Knabbe, Cornelius
TI  - A combined strategy to detect plasma samples reliably with high anti-SARS-CoV-2 neutralizing antibody titers in routine laboratories
AID  - 10.1101/2021.03.15.21253588
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.15.21253588
4099  - http://medrxiv.org/content/early/2021/03/19/2021.03.15.21253588.short
4100  - http://medrxiv.org/content/early/2021/03/19/2021.03.15.21253588.full
AB  - The determination of anti-SARS-CoV-2 neutralizing antibodies (NAbs) is of interest in many respects. High NAb titers, for example, are the most important criterion regarding the effectiveness of convalescent plasma therapy. However, common cell culture-based NAb assays are time-consuming and feasible only in special laboratories. Our data reveal the suitability of a novel ELISA-based surrogate virus neutralization test (sVNT) to easily measure the inhibition-capability of NAbs in the plasma of COVID-19 convalescents. We propose a combined strategy to detect plasma samples with high NAb titers (≥ 1:160) reliably and to, simultaneously, reduce the risk of erroneously identifying low-titer specimens. For this approach, results of the sVNT assay are compared to and combined with those acquired from the Euroimmun anti-SARS-CoV-2 IgG assay. Both assays are appropriate for high-throughput screening in standard BSL-2 laboratories. Our measurements further show a long-lasting humoral immunity of at least 11 months after symptom onset.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All donors underwent a medical examination before donation. Samples were collected in accordance with the German Act on Medical Devices for the collection of human residual material. Ethical approval was obtained from the ethical committee of the HDZ NRW in Bad Oeynhausen (Reg. No. 670/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during the current study are available from the corresponding author on reasonable request.SARS-CoV-2Severe acute respiratory syndrome coronavirus type 2COVID-19Coronavirus Disease 2019NAbsNeutralizing antibodiesBabsBinding antibodies